Life360 Innovations hires Director Professional Sales & Medavie Blue Cross Initiates Contino® Coverage
Vancouver, BC/February 17, 2021 — Life360 Innovations is pleased to announce that Iris Kalbfleisch has joined the Company as Director Professional Sales and Medavie Blue Cross has initiated coverage of Contino®.
Iris Kalbfleisch is a 25+ year sales professional with the bulk of her experience within the pharmaceutical industry having worked with Pfizer Canada in progressive roles including specialty pharmaceutical sales representative. In addition, Ms. Kalbfleisch has consulted to 29 of the top 30 pharmaceutical companies in a range of areas including benchmarking top performing sales individuals against KPIs for strategic alignment of sales and marketing teams to accelerate high performance.
“On behalf of the management team and boards we are delighted to welcome Iris to the team” stated Robert Orr, CEO, Life360 Innovations. Orr goes on to state, “Ms. Kalbfleisch will test and design our healthcare professionals’ awareness and outreach campaigns currently underway in BC, which will help accelerate our sales growth as we expand across Canada and internationally in the years to come.“
Effective immediately Medavie Blue Cross has initiated coverage of Contino®. Medavie Blue Cross has been a leading health services partner for 75+ years to individuals, employers and governments across Canada and is the country’s leading Blue Cross plan with over one million card holders.
“We thank Medavie Blue Cross for initiating coverage of the Contino® urethral insert, which is now covered by ten major insurance providers across Canada,” stated Robert Orr, who goes on to state: “this coverage should help more men access Contino® and help build awareness of our first of its kind male urinary incontinence medical device.”
About Life360 Innovations Inc.
Life360 Innovations (life360innovations.com/) is a Canadian private company that imagines, manufactures and distributes licensed medical devices through a proprietary partner network. For more information contact: